BNT162b2 Effective for Children, Teens During Delta, Omicron Waves

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

MONDAY, Jan. 8, 2024 -- In children and adolescents, BNT162b2 was effective for COVID-19-related outcomes during the delta and omicron periods, according to a study published online Jan. 9 in the Annals of Internal Medicine.

Qiong Wu, Ph.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined the effectiveness of BNT162b2 with different strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in previously uninfected children. Effectiveness was examined among 77,392 adolescents (45,007 vaccinated) during the delta phase and 111,539 children (50,398 vaccinated) and 56,080 adolescents (21,180 vaccinated) during the omicron phase.

The researchers found that the estimated effectiveness of the BNT162b2 vaccine was 98.4 percent against documented infection among adolescents during the delta period, with no significant waning observed after receipt of the first dose. No significant difference was seen in cardiac complications between vaccinated and unvaccinated groups. The effectiveness against documented infection during the omicron period was estimated to be 74.3 percent among children, with higher effectiveness observed against moderate or severe COVID-19 (75.5 percent) and intensive care unit admission with COVID-19 (84.9 percent). Among adolescents, the corresponding effectiveness was 85.5, 84.8, and 91.5 percent. There was a decline noted in the effectiveness of the BNT162b2 vaccine against the omicron variant four months after the first dose, which then stabilized. During the omicron period, the risk for cardiac complications was lower in the vaccinated group.

"Our assessment of vaccine effectiveness across diverse outcomes underscores the vaccine's pivotal role in reducing SARS-CoV-2 transmission, minimizing COVID-19-related sick leaves, and alleviating economic burdens during the pandemic," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords